Trial Profile

Open-label Dose-finding and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART20x22 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etivelcabtagene erigedleucel (Primary) ; Alemtuzumab; Cyclophosphamide; Fludarabine
Indications B-cell lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; First in man
Acronyms NatHaLi-01
Sponsors Cellectis

08 Dec 2025 According to a Cellectis media release, the full Phase 1 dataset expected in 2026.
08 Dec 2025 According to a Cellectis media release,updated data of patients from this trial presented at the 67th Annual Meeting of the American Society of Hematology (ASH) in Orlando, FL.
07 Nov 2025 event According to a Cellectis media release, data from the trial were presented at the R&D Day.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com